Heart failure & cardiomyopathiesCohort study
Heart failure in Europe: Guideline‐directed medical therapy use and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the European Society of Cardiology (ESC) EORP Heart Failure III Registry
- Prospective registry study
- multicentre
- 220 centres in 41 European or ESC-affiliated countries
Authors' conclusion
Use and initiation of GDMT was high in cardiology centres in Europe, compared to previous reports from cohorts and registries including more primary care and general medicine and regions more local or outside of Europe and ESC-affiliated countries.
Study context
- Population
- Patients with acute Heart Failure (HF) or outpatient HF visit, ESC HF III Registry, Nov 2018–Dec 2020
- Participants
- 10,162 patients · 220 centres · 41 countries
- Exposure
- HFrEF vs HFmrEF vs HFpEF
Main finding
As reported in the abstract
GDMT use after the AHF event or outpatient HF visit
Any RAS inhibitor
ARNI
Beta-blocker
MRA
Loop diuretics
Observational data: associations, not effects.
Further findings
De novo HF
Original publication
Heart failure in Europe: Guideline‐directed medical therapy use and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry. Eur J Heart Fail. Published 10 September 2024. doi:10.1002/ejhf.3445
Summarised from the published abstract; every number is checked against it